rodent data — 9 things I got wrong before I got it right
The title is the argument: rodent data — 9 things I got wrong before I got it right. Here is the rest of it.
Ask for the theoretical mass alongside the measured one. It is a one-line addition to a certificate and it converts a purity claim into an identity claim.
Research-use-only material is not approved for human use. In this board that is not a formality — it is the reason the clinical evidence base is as thin as it is.
Regulatory classification differs between jurisdictions and has changed in several of them recently. Any answer to a status question needs a place and a date attached.
Not medical advice, obviously, and nothing here is approved for human use. One person with a spreadsheet.
best — the order this archive was captured in
Purity by area percent tells you the sample is homogeneous. Mass spectrometry tells you what the homogeneous thing is. For a short peptide, the second question is the one worth paying for.
Purity by area percent tells you the sample is homogeneous.
This is the point that should be at the top of every thread here. Identity first.
The published literature is overwhelmingly preclinical, largely in rodent models. Translating a rodent result into a human expectation is not a small step, and almost every confident claim here takes it silently.
[removed by moderator]
Every claim I could trace in this board went back to about four papers. That was a sobering afternoon.
Yes — the rodent literature is real and it is rodent literature. The gap to a human claim is enormous and it gets crossed in one sentence here.
Is that a clinical claim or a preclinical one?
the human evidence is thin and the rodent evidence is not
most of the claims here trace to the same handful of rodent papers
Left up. It distinguishes rodent work from human work, which is the standard on this board.
What method produced that purity number?
Went and read the primary rodent papers after arguing about a summary for a week. They are much narrower than the threads suggest.
It is a fifteen-residue peptide with a published sequence, which makes synthesis straightforward and makes identity verification the meaningful test rather than an optional extra.
no clinical trial has established what these threads assert
Disagree — that is a rodent study and you are stating it as a human effect. The distance between those is the entire argument.
That is a purity figure, not an identity confirmation. Two different tests and only one answers the question asked.
Short peptides in solution are subject to hydrolysis and, depending on sequence, oxidation. Storage state and time in solution are practical variables that this board almost never discusses.
Has anyone posted an independent result on that batch?
Assumed regulatory status was static and it was not. Checked again this year and the answer had changed where I live.
identity testing matters more here than purity does
regulatory status varies by jurisdiction and it has moved recently
Not convinced. A high purity figure with no identity confirmation tells you the sample is homogeneous, not that it is what you ordered.
Not convinced.
Disagreeing with this line: that paper is in a rodent model and it is being quoted as a human result.
preclinical enthusiasm is not clinical evidence
research-use-only means not approved for human use, and here that covers everything
ask for the mass spectrum, not just the purity number
short peptides are cheap, which cuts both ways
Was there identity confirmation, or only a purity figure?
Push back: "no reported harms" in a literature with almost no human trials is not a safety finding.
- 1It is a fifteen-residue peptide with a published sequence, which makes…15 comments in this branch · started by u/cloudy_vial_carol
- 2The published literature is overwhelmingly preclinical, largely in rodent…6 comments in this branch · started by u/adaeze_krastev